# Study to Evaluate the Safety and Tolerability of CC-92328 in Participants With Relapsed and/or Refractory Multiple Myeloma

> **NCT04975399** · PHASE1 · TERMINATED · sponsor: **Celgene** · enrollment: 26 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** CC-92328

## Key facts

- **NCT ID:** NCT04975399
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-10-05
- **Primary completion:** 2024-06-18
- **Final completion:** 2024-06-18
- **Target enrollment:** 26 (ACTUAL)
- **Why stopped:** Business objectives have changed
- **Last updated:** 2025-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04975399

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04975399, "Study to Evaluate the Safety and Tolerability of CC-92328 in Participants With Relapsed and/or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04975399. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*